Comments

KalVista Pharma

KALVNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$14.48
-0.66-4.36%
Pre-Market: 5:17 PM EDT
15 minutes delayed
KalVista Pharma (KALV) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesGovernment TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$32.00
Lowest Price Target1
$20.00
Consensus Price Target1
$24.80

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

KalVista Pharma (NASDAQ:KALV) Stock, Analyst Ratings, Price Targets, Forecasts

KalVista Pharmaceuticals Inc has a consensus price target of $24.8 based on the ratings of 5 analysts. The high is $32 issued by Needham on July 12, 2024. The low is $20 issued by HC Wainwright & Co. on July 15, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Needham, and Needham on July 15, 2024, July 12, 2024, and June 18, 2024, respectively. With an average price target of $29 between HC Wainwright & Co., Needham, and Needham, there's an implied 100.28% upside for KalVista Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
0
0
0
0
May
0
0
0
0
Jun
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Needham
Cantor Fitzgerald
SVB Leerink
Stifel

1calculated from analyst ratings

Analyst Ratings for KalVista Pharma

Buy NowGet Alert
07/15/2024Buy Now38.12%HC Wainwright & Co.
Andrew Fein
$20 → $20ReiteratesBuy → BuyGet Alert
07/12/2024Buy Now120.99%Needham
Serge Belanger
$35 → $32MaintainsBuyGet Alert
06/18/2024Buy Now141.71%Needham
Serge Belanger
$35 → $35ReiteratesBuy → BuyGet Alert
05/03/2024Buy Now38.12%HC Wainwright & Co.
Andrew Fein
$24 → $20MaintainsBuyGet Alert
05/01/2024Buy Now141.71%Needham
Serge Belanger
 → $35ReiteratesBuy → BuyGet Alert
04/11/2024Buy Now141.71%Needham
Serge Belanger
 → $35ReiteratesBuy → BuyGet Alert
03/12/2024Buy Now65.75%HC Wainwright & Co.
Andrew Fein
 → $24ReiteratesBuy → BuyGet Alert
03/11/2024Buy Now141.71%Needham
Serge Belanger
$35 → $35MaintainsBuyGet Alert
02/14/2024Buy Now65.75%HC Wainwright & Co.
Andrew Fein
$16 → $24MaintainsBuyGet Alert
02/13/2024Buy Now141.71%Needham
Serge Belanger
$22 → $35MaintainsBuyGet Alert
09/08/2023Buy Now10.5%HC Wainwright & Co.
Andrew Fein
 → $16ReiteratesBuy → BuyGet Alert
08/22/2023Buy Now38.12%Cantor Fitzgerald
Charles Duncan
 → $20ReiteratesOverweight → OverweightGet Alert
07/10/2023Buy Now10.5%HC Wainwright & Co.
Andrew Fein
 → $16ReiteratesBuy → BuyGet Alert
04/21/2023Buy Now51.93%Needham
Serge Belanger
 → $22Reiterates → BuyGet Alert
03/10/2023Buy Now127.9%Cantor Fitzgerald
Charles Duncan
$49 → $33MaintainsOverweightGet Alert
03/10/2023Buy Now10.5%HC Wainwright & Co.
Andrew Fein
 → $16Reiterates → BuyGet Alert
03/09/2023Buy Now51.93%Needham
Serge Belanger
$24 → $22Reiterates → BuyGet Alert
02/03/2023Buy Now38.12%SVB Leerink
Joseph Schwartz
$30 → $20MaintainsOutperformGet Alert
10/06/2022Buy Now10.5%HC Wainwright & Co.
Andrew Fein
$48 → $16MaintainsBuyGet Alert
10/05/2022Buy Now107.18%SVB Leerink
Joseph Schwartz
$45 → $30MaintainsOutperformGet Alert
10/04/2022Buy Now65.75%Needham
Serge Belanger
$38 → $24MaintainsBuyGet Alert
07/08/2022Buy Now210.77%SVB Leerink
Joseph Schwartz
$51 → $45MaintainsOutperformGet Alert
07/08/2022Buy Now162.43%Needham
Serge Belanger
$42 → $38MaintainsBuyGet Alert
06/08/2022Buy Now120.99%Stifel
Paul Matteis
$54 → $32MaintainsBuyGet Alert
03/11/2022Buy Now190.06%Needham
Serge Belanger
$48 → $42MaintainsBuyGet Alert
12/10/2021Buy Now231.49%Needham
Serge Belanger
—MaintainsBuyGet Alert

FAQ

Q

What is the target price for KalVista Pharma (KALV) stock?

A

The latest price target for KalVista Pharma (NASDAQ:KALV) was reported by HC Wainwright & Co. on July 15, 2024. The analyst firm set a price target for $20.00 expecting KALV to rise to within 12 months (a possible 38.12% upside). 12 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for KalVista Pharma (KALV)?

A

The latest analyst rating for KalVista Pharma (NASDAQ:KALV) was provided by HC Wainwright & Co., and KalVista Pharma reiterated their buy rating.

Q

When was the last upgrade for KalVista Pharma (KALV)?

A

There is no last upgrade for KalVista Pharma

Q

When was the last downgrade for KalVista Pharma (KALV)?

A

There is no last downgrade for KalVista Pharma.

Q

When is the next analyst rating going to be posted or updated for KalVista Pharma (KALV)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KalVista Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KalVista Pharma was filed on July 15, 2024 so you should expect the next rating to be made available sometime around July 15, 2025.

Q

Is the Analyst Rating KalVista Pharma (KALV) correct?

A

While ratings are subjective and will change, the latest KalVista Pharma (KALV) rating was a reiterated with a price target of $20.00 to $20.00. The current price KalVista Pharma (KALV) is trading at is $14.48, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch